Pembrolizumab plus ADG106 for advanced triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This early-phase study tests pembrolizumab (an immune therapy) combined with ADG106 in people with advanced solid tumors, and specifically triple-negative breast cancer. It looks at whether the treatment can shrink tumors and improve outcomes for cancers that are progressing despite prior therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be age 21 or older.
- Your cancer must be advanced or metastatic, and imaging should show it is growing.
- For the breast-cancer part of the study: your tumor must be triple-negative with specific lab results (ER/PR <1% and HER2 is 0–2+ but HER2 FISH negative).
- You must be able to undergo a tumor biopsy before starting treatment.
- You need to be well enough to do daily activities (ECOG 0–1) and have adequate blood, liver, kidney, and clotting test results.
- You must not have certain recent treatments or active infections/autoimmune problems, and you must avoid pregnancy during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if giving more of the immunotherapy drug pembrolizumab (Keytruda) after surgery helps people with early-stage triple-negative breast cancer that did not completely disappear with the initial chemotherapy plus immunotherapy. This is for patients who still have some cancer left after surgery, to reduce the chance of it coming back.
This trial studies whether adding pembrolizumab (an immunotherapy) to standard chemotherapy after surgery can improve outcomes for people with early-stage triple-negative breast cancer. The treatment you receive depends on the level of immune cells (TILs) found in your tumor.
This Phase 2 trial studies a treatment plan given before surgery (neoadjuvant) and after surgery (adjuvant) for people with BRCA1/2-mutated triple negative breast cancer that has not spread. It aims to improve how well the cancer responds and how long people stay cancer-free.
This trial tests whether adding an experimental drug called INBRX-106 to the standard immunotherapy (pembrolizumab) and chemotherapy before surgery can improve outcomes for patients with early-stage triple-negative breast cancer. The goal is to shrink the tumor and potentially reduce the risk of the cancer coming back.
This trial tests two different sequences of chemotherapy combined with pembrolizumab (an immunotherapy drug) given before surgery for high-risk triple-negative breast cancer. The goal is to see which sequence works better at shrinking or eliminating the tumor.
This early-phase study tests a new treatment in people with advanced (locally advanced or metastatic) solid tumors that have worsened or cannot be treated with standard therapies. It may help shrink tumors or slow growth, and it also helps doctors learn the safest way to use the medicine.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.